Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Grist E, et al. Genome Medicine. 2022
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
Feng F, et al. JAMA Oncol. 2021
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Gilson C, et al. JCO Precision Oncology. 2020
Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Attard G, et al. Clin Cancer Res. 2015
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J, et al. Cancer Res. 2012